Avidbank Holdings (AVBH) Stock Climbs As Q3 Earnings Revive Profitability

Simply Wall St · 1d ago

Avidbank Holdings stock closed at US$32.72 today, up 3.6%, as investors reacted quickly to fresh Q3 2026 results. The initial move looks upbeat. The main focus, though, is the earnings power underlying that price move. Quarterly earnings per share came in at about US$0.96 on revenue of roughly US$29.2m, helping extend the bank’s return to profit over the last twelve months. Short term traders are trading the pop. Long term holders are weighing what this newer, cleaner profitability profile means in relation to the valuation and the earlier multi year earnings slump.

Love the cleaner return to profit at Avidbank Holdings but concerned about getting caught in another earnings slump story? Screen for banks with steadier profitability profiles in our list of solid balance sheet and fundamentals stocks (24 results)

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$29.2m vs. a reported revenue loss of US$39.6m (a swing back to a positive top line)
  • Net Income (Q3 2026 vs. Q3 2025): US$10.2m profit vs. a loss of US$37.7m (moved from a deep loss to solid profitability)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$0.96 per share vs. a loss of US$4.12 per share (a sharp improvement in per share earnings)
  • Trailing 12 Month Revenue (Q3 2026 vs. Q3 2025 TTM): US$106.6m vs. US$82.1m (higher revenue over the last year)

Tired of scrolling through walls of text and raw bank earnings tables? See Avidbank Holdings' full financial picture, including a clear view of its recent profitability shift, in our interactive company report for Avidbank Holdings.

NasdaqGS:AVBH Trailing 12-Month Earnings & Revenue History as at Oct 2026
NasdaqGS:AVBH Trailing 12-Month Earnings & Revenue History as at Oct 2026

Avidbank bullish narrative meets early profitability milestones

The optimistic view on Avidbank Holdings hangs on using fresh capital and deposit strength to reshape earning assets and improve resilience.

"The reinvestment of US$163 million into mortgage backed CMOs at an average yield of 4.54% and the plan to keep the securities portfolio at roughly 10% to 15% of earning assets point to a more focused use of the balance sheet toward loans and higher yielding instruments."

Q3 2026 results show this repositioned book feeding a 4.07% net interest margin and 1.42% ROAA alongside a sub 50% efficiency ratio. Broad based loan growth and controlled credit metrics support the idea that the higher yielding mix is translating into healthier earnings power, even with some margin pressure from temporary deposits.

Bear case on funding and competition not fully resolved

On the risk side, the critical question is whether Avidbank Holdings can defend funding costs and credit quality while leaning into niche lending.

"The bank is targeting a loan to deposit ratio around the mid 90% range and relies on ongoing loan and deposit growth in niche areas like venture and fund finance."

Q3 shows core deposits rising about US$76m, yet the US$270m temporary balance that is expected to exit highlights funding volatility. Core spot deposit costs moved to roughly 3.30% and management acknowledges competitive pressure, so the targeted loan to deposit balance and margin durability still face a live test rather than a closed issue.

One Narrative disagrees with today's price. → See where this Narrative says Avidbank Holdings should trade.

Hunt For Mispriced Earnings Power

Avidbank Holdings recently highlighted how a sharper earnings profile can reshape a stock narrative. The real opportunity is in stocks that may be undervalued before the market fully reassesses their earnings power.

  • Company 1 - 27% below our estimate - turns rising grid modernization and aerospace program demand into higher margin diagnostic and RF testing projects.
  • Company 2 - 46% below our estimate - converts record data center focused backlog into higher value mechanical and electrical projects using modular builds.
  • Company 3 - 23% below our estimate - expands robotic surgery platforms into new joint procedures while reworking manufacturing and supply chains for better economics.

That is three of the list. See all 29 potentially undervalued companies →